Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

View original at finance.yahoo.com
“lifted cash to $18.2B at year-end 2025 from $3.3B a year earlier.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AT&T legacy wireline revenue declined more than 20% in 2026

    60% confidence
  • Analyst consensus target price for Pfizer is $29.19

    60% confidence
  • Analyst target price for SoFi Technologies is $21.10

    60% confidence
  • Pfizer's non-COVID portfolio achieved 9% operational revenue growth

    60% confidence
  • AT&T's converged connectivity and growing free cash flow makes the dividend durable

    60% confidence
  • Pfizer faces a $1.5 billion revenue headwind in 2026 from loss of drug exclusivity and Most Favored Nation drug pricing pressure

    60% confidence
  • SoFi Q1 2026 net income increased 134% year-over-year to $166.7 million

    60% confidence
  • Equity markets are trading at elevated multiples in May 2026

    60% confidence
  • AT&T grew its cash position from $3.3 billion at year-end 2024 to $18.2 billion at year-end 2025

    60% confidence
  • SoFi Q1 2026 loan originations reached a record $12.18 billion, up 68% year-over-year

    60% confidence
  • Analyst target price for AT&T is $30.37

    60% confidence
  • AT&T Q1 2026 adjusted EPS grew 11.8% year-over-year to $0.57

    60% confidence

Data points we hold from this source

AT&T Inc. · debt173.99 USD
AT&T Inc. · analyst target price30.37 USD
AT&T Inc. · forward pe11 multiple
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com